Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $23,717,000 | reported | |
| FY 2024 | 2024-12-31 | $34,426,000 | reported | |
| FY 2023 | 2023-12-31 | $33,770,000 | reported | |
| FY 2022 | 2022-12-31 | $35,017,000 | reported | |
| FY 2021 | 2021-12-31 | $20,015,000 | reported | |
| FY 2020 | 2020-12-31 | $14,444,000 | reported | |
| FY 2019 | 2019-12-31 | $9,824,000 | reported | |
| FY 2018 | 2018-12-31 | $8,372,000 revised | reported | |
| FY 2017 | 2017-12-31 | $2,881,000 | reported | |
| FY 2016 | 2016-12-31 | $5,678,000 | reported | |
| FY 2015 | 2015-12-31 | $3,992,000 | reported | |
| FY 2014 | 2014-12-31 | $5,805,000 | reported |
Armata Pharmaceuticals, Inc. · CIK 921114 · Engraved from SEC EDGAR
FY2025 figures · derived
Armata Pharmaceuticals, Inc. is the 101st largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
Latest filing Nov 12, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2016 | $80.00K | — | $80.00K | — | 16.49M sh | +180.2% | — |
63 managers · Quarter ended Sep 30, 2026All holders ›
14No reported open-market purchases or sales in the last 12 months.